BioPharma Dive Apr 29, 2026 FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
BioPharma Dive Apr 28, 2026 FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
BioPharma Dive Apr 28, 2026 Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
BioPharma Dive Apr 24, 2026 Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
BioPharma Dive Apr 23, 2026 Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs